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Abstract 27 
Recent advances have been made in the study of urinary proteomics as a diagnostic tool for renal 28 
disease and pre-eclampsia which requires accurate measurement of urinary protein. We compared 29 
different protein assays (Bicinchoninic acid (BCA), Lowry and Bradford) against the ‘gold standard’ 30 
amino-acid assay in urine from 43 women (8 non-pregnant, 34 pregnant, including 8 with pre-31 
eclampsia. BCA assay was superior to both Lowry and Bradford assays (Bland Altman bias: 0.08) 32 
compared to amino-acid assay, which performed particularly poorly at higher protein concentrations. 33 
These data highlight the need to use amino-acid or BCA assays for unprocessed urine protein 34 
estimation. 35 
 36 
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Background 42 
Protein excretion in urine is associated with many pathologies including the pregnancy specific 43 
syndrome pre-eclampsia. Characterising specific proteins in urine is now achievable through advances 44 
in proteomic technologies and the use of urine as a source of candidate biomarkers and therapeutic 45 
targets is rapidly developing.  Recently proteomic techniques have identified potential diagnostic and 46 
predictive urinary biomarkers for pre-eclampsia [1-4].  47 
Urine protein estimation of different clinical laboratory techniques have previously been tested but this 48 
has not been completed for standard research methods [5]. Proteomic analysis requires precise 49 
assessment of total protein concentrations to enable accurate quantitation by subsequent downstream 50 
gel-based and tandem mass spectrometry (MS/MS) [6], and is a requisite to confidently explore the role 51 
of future biomarkers. 52 
Whilst there is a move to standardise urine collection for urinary proteomic assessment by the Human 53 
Human Kidney and Urine Proteome Project (HKUPP) and the European Kidney and Urine Proteomics 54 
(EuroKUP) networks (www.hkupp.org; www.eurokup.org;), publications on urinary proteomics use a 55 
variety of assays to estimate total protein concentrations (e.g. Bradford and Coomassie Plus assays,[7-56 
11] BCA)[12, 13] or assays are not defined. However, these tests were not specifically developed to 57 
quantify protein in urine and may suffer inaccuracies due to interference by urinary solutes or pH. High 58 
urea concentrations are also likely to interfere with Bradford assay due to the incompatibility of 59 
coomassie based protein assays to surfactants, e.g. urea, even at low concentrations, causes precipitation 60 
of the reagent [14]. 61 
 62 
The objective of this study was to assess which protein assay provided the most accurate quantification 63 
across a wide range of urinary protein concentrations.  We performed three standard assays 64 
(Bicinchoninic acid (BCA), Lowy and Bradford) and compared these to the current gold standard amino-65 
acid assay. 66 
 67 
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Methods 68 
Sample collection 69 
Urine samples with a diverse range of protein concentrations were collected from healthy pregnant 70 
women at 15 weeks’ (n = 12) and 20 weeks’ (n = 12) gestation. Urine samples were also collected from 71 
women who had been diagnosed with pre-eclampsia (n = 8); according to International Society of Study 72 
of Hypertension in Pregnancy Guidelines[15] and from healthy non-pregnant women of reproductive 73 
age (n = 8). All collections were approved by the St. Thomas’ Local Ethics Committee (09/H0802/031) 74 
and obtained following informed written consent. Once collected, urine samples were centrifuged at 75 
1400 x g for 10 minutes at 4oC and then stored in aliquots at -80oC until required for protein 76 
concentration assays.   77 
 78 
Protein estimation of urine 79 
Prior to protein concentration assays, urine aliquots (1.8 ml) were ultracentrifuge concentrated to 80 
approximately 170 μL using a 3,000 MW filtration column (Millipore Centrifugal Filter Units). Protein 81 
concentration was first estimated using the amino acid assay. Subsequent assays using the Lowry, 82 
BCA and Bradford assays (Thermo Scientific) were then performed on the same urine samples 83 
following manufacturers’ protocols after urine dilutions for each sample set and assay were optimised to 84 
fit within the recommended standard curve concentration ranges. 85 
 86 
Statistical analysis 87 
Initial visual analysis was completed by scatter plots comparing each of the three protein assays with 88 
the amino acid assay. The amino acid assay results were then compared to the other assays using the 89 
Bland-Altman method. For each pair of measures, the average and difference were calculated; and 90 
95% reference ranges defined as the mean of the differences ± 1.96 x SD. The closer the reference 91 
range is to zero, the closer the agreement between the methods of measurement [16]. 92 
 93 
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 94 
Results  95 
Of the three spectrophotometric assays tested, the BCA compared closest to amino acid analysis for 96 
determining the protein concentration in urine (Fig. 1a). Furthermore, the Bland Altman test indicated 97 
the BCA assay produced similar results to the gold standard amino acid assay (Table 1 and Figure 2). 98 
Both the Bradford and Lowry assays greatly underestimated the protein concentration in the urine 99 
samples. There were no differences in the performance of assays between non-pregnant and pregnant 100 
urine samples, indicating the BCA assay in particular has utility for determining urinary protein 101 
concentrations in both pregnant and non-pregnant conditions. 102 
We conducted an evaluation comparing the standard laboratory assays against the gold standard 103 
amino acid assay.  Samples from pregnant and non-pregnant women were used to ensure that a range 104 
of protein concentrations were assessed.  The BCA performed considerably better and outperformed 105 
the Lowry and Bradford assays.   106 
 107 
Discussion 108 
Urine is an attractive source of potential clinical biomarkers due to the large quantities available and 109 
non-invasive nature of collection.  Proteomic analysis not only gives insight into biological processes 110 
within the kidney and urogenital tract, but due to glomerular filtration of a subject’s blood, circulating 111 
biomarkers may also be identified.  The complexity of the urinary proteome is rapidly evolving with the 112 
development of MS based approaches and over 3500 proteins have now been isolated detected as 113 
excreted under different conditions [6, 11, 13, 17].   114 
 115 
Although urine is readily available in large quantities, its low and variable protein concentration, salt 116 
content and other potential contaminants make multiple purification and preparation steps necessary 117 
for proteomic analysis.  Whilst there has been considerable progress in exploration and standardisation 118 
of urine sample collection [18] and downstream analytical methodologies, reviewed by ourselves [6], 119 
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and there is a paucity of data regarding which bench protein assay is most appropriate for urine protein 120 
quantification.  Due to the multiple steps required prior to proteomic analysis a great deal of variability 121 
may be introduced, which may compromise validity of results, particularly those assessing biomarker 122 
quantification. As one of these steps involves assessment of total protein concentration in each urine 123 
sample in order to process the desired amount of protein for mass spectrometric analysis, an accurate 124 
reproducible protein assay is fundamental to every urinary proteomic workflow.     125 
 126 
The amino acid assay is considered the gold standard for protein quantification; however it is both 127 
expensive and time consuming, therefore for routine urinary protein quantification assay that may be 128 
performed in a routine laboratory setting is desirable. 129 
In conclusion, we have identified the BCA protein assay to be a suitable alternative to the amino acid 130 
analysis gold standard for the accurate assessment of total protein in urine samples. We recommend it 131 
as a rapid technique that can be performed in the local laboratory environment for all urinary proteomic 132 
workflows, to reduce inherent variability in protein concentration estimates and enable more robust 133 
quantitative proteomic analysis. 134 
 135 
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Table & Figure legends 218 
Table 1: Bland-Altman bias and limits of agreement for all assays compared to the amino acid assay 219 
Figure 1: Scatter plots comparing the amino acid assay (AAA) with a) BCA; b) Bradford assay; and c) 220 
Lowry assay. Dashed reference lines are y=x.  221 
Figure 2: Bland-Altman plot comparing the amino acid assay (AAA) with the BCA indicating that the 222 
BCA method is most comparable. 223 
 224 
Table 1: 225 
Assay Comparison Bias 95% Limit of Agreement 
From  Till 
Bradford Assay vs. 
Amino Acid Assay 
-1.7 - 6.9 3.5 
 
BCA vs. Amino Acid 
Assay 
0.08 -0.7 0.9 
 
Lowry Assay vs. 
Amino Acid Assay 
-2.4 -7.0 2.3 
 226 
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